Moreover, they are important components of the recently approved drug class of angiotensin receptor neprilysin inhibitors (ARNi) that combine pharmacological neprilysin inhibition with an ARB moiety for the effective treatment of chronic heart failure with reduced ejection fraction (Yancy et al., 2016). The gene discussed is MME; the disease is congestive heart failure.